ID Biomedical gains NIH grant to develop nasally delivered plague vaccine

November 2004
PharmaWatch: Biotechnology;November 2004, Vol. 3 Issue 11, p5
Market Research Report
Reports that ID Biomedical has been awarded grant by the U.S. National Institutes of Health to develop a nasally delivered plague vaccine based on its proprietary, intranasal, Proteosome adjuvant/delivery technology. Aim to develop a sub-unit plague vaccine using a recombinant plague antigen, the FIV protein; Inclusion of preclinical and early stage clinical trials in which the vaccine's safety and immunogenicity will be studied.


Related Articles

  • ID BIOMEDICAL INITIATES STREPTAVAX CLINICAL TRIAL.  // Worldwide Biotech;Sep2001, Vol. 13 Issue 9, p1 

    No abstract available.

  • Women still face many hurdles to clinical trial participation. Steimle, Sabine // JNCI: Journal of the National Cancer Institute;04/16/97, Vol. 89 Issue 8, p545 

    Discusses the challenges faced by women in their attempt to participate in clinical trials in the United States. Experience of Patty Delaney; Significance of the enactment of the National Institutes of Health Revitalization Act of 1993; Moral and ethical issues concerning clinical trials;...

  • Phase II data shows strong immunogenicity for ID Biomedical's FluINsure.  // PharmaWatch: Biotechnology;August 2003, Vol. 2 Issue 8, p7 

    Focuses on the clinical trials for FlulNsure, an intranasal, non-live, influenza vaccine developed by ID Biomedical Corp. Patients enrolled in the study; Presentation of the clinical study of FlulNsure; Evaluation on the efficacy of the influenza vaccine.

  • Federal Government Offers Funds for Diabetes Research Centers.  // Children & Youth Funding Report;1/9/2009, p12 

    The article informs that funding opportunity is being issued by the Health & Human Services Department of the U.S. to support clinical centers which will participate in studies aimed at preventing or delaying the onset or progression of type 1 diabetes (T1D) as part of the TrialNet clinical...

  • Biobanking for research in surgery: are surgeons in charge for advancing translational research or mere assistants in biomaterial and data preservation? Thasler, Wolfgang; Thasler, Reinhard; Schelcher, Celine; Jauch, Karl-Walter // Langenbeck's Archives of Surgery;Apr2013, Vol. 398 Issue 4, p487 

    Background: High-quality biospecimens of human origin with annotated clinical and procedural data are an important tool for biomedical research, not only to map physiology, pathophysiology and aetiology but also to go beyond in translational research. This has opened a new special field of...

  • NHS research programme to be transformed. Cole, Andrew // BMJ: British Medical Journal (International Edition);8/13/2005, Vol. 331 Issue 7513, p368 

    Discusses the British government's plans to boost NHS research. Speculation on whether the research will go far enough to address the crisis in academic medicine; Claim by the health department for England that it plans to transform the way clinical research is funded and structured; Details of...

  • Puerto Rican government offers support for country's cancer center. Brower, Vicki // JNCI: Journal of the National Cancer Institute;6/16/2004, Vol. 96 Issue 12, p901 

    Reports on the funds given by the government for its cancer research center in Puerto Rico. Development of a cancer research hospital; Impact of the center on the care of cancer patients; Lack of clinical trials available to patients.

  • Studying Episiotomy: When Beliefs Conflict with Science. Klein, Michael C. // Journal of Family Practice;Nov1995, Vol. 41 Issue 5, p483 

    In 1984, we proposed to study the need for episiotomy in the first North American randomized controlled trial on this subject. Getting funded and published proved to be difficult since we were questioning not only established views on episiotomy but also conventional beliefs about birth. During...

  • Personalized medicine: Time for one-person trials. Schork, Nicholas J. // Nature;4/30/2015, Vol. 520 Issue 7549, p609 

    The author argues that one-person or N-of-1 clinical trials should be used to measure individual responses to therapy as an aspect of precision medicine. Topics include the U.S. government's Precision Medicine Initiative, the inefficiency of clinical trials targeting genetic groups, and the use...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics